Militia Capital Management LLC Acquires New Position in uniQure N.V. $QURE

Militia Capital Management LLC purchased a new position in uniQure N.V. (NASDAQ:QURE) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 94,200 shares of the biotechnology company’s stock, valued at approximately $1,540,000.

Several other institutional investors and hedge funds have also recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 5.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares in the last quarter. Arizona State Retirement System grew its stake in shares of uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in shares of uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the 3rd quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Insider Activity

In other news, insider Kylie O’keefe sold 15,936 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider directly owned 108,864 shares in the company, valued at approximately $2,945,859.84. This trade represents a 12.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 433,229 shares of company stock valued at $17,944,799 over the last quarter. Insiders own 4.65% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a report on Wednesday, June 17th. HC Wainwright boosted their target price on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a research note on Wednesday. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Mizuho boosted their price objective on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Stock Performance

NASDAQ QURE opened at $43.63 on Monday. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a 50 day moving average price of $37.49 and a 200 day moving average price of $26.28. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The firm has a market cap of $3.03 billion, a PE ratio of -10.88 and a beta of 0.93.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same period in the prior year, the business posted ($0.69) EPS. As a group, sell-side analysts forecast that uniQure N.V. will post -3.74 EPS for the current fiscal year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: An analyst raised uniQure’s price target to $75, signaling additional potential upside and supporting investor sentiment. uniQure Price Target Raised to $75.00
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target. Its projections still anticipate a shift from losses to profitability over the longer term, including estimated positive EPS of $1.95 in fiscal 2029 and $5.07 in fiscal 2030.
• Neutral Sentiment: The target-price increase provides a constructive valuation signal, although it remains below HC Wainwright’s $80 objective, leaving analysts’ views somewhat mixed.
• Negative Sentiment: HC Wainwright reduced EPS estimates across multiple periods, including fiscal 2026 to a loss of $3.98 per share from $3.38, fiscal 2027 to a loss of $3.87 from $3.46, and fiscal 2028 to a loss of $1.07 from $0.64. The firm also lowered its fiscal 2029 and 2030 profit forecasts, indicating expectations for weaker near- and long-term earnings.
• Negative Sentiment: Wall Street Zen downgraded QURE to a “Sell” rating, adding a bearish counterpoint to the more optimistic HC Wainwright view. uniQure Downgraded to Sell Rating

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.